Supplementary Information

Figure and Table Legends

Supplementary Figure 1. Overview of the bandit task sequence. The three blue squares in every screenshot indicate the individual bandits. After selecting the bandit with the keypad, the points won are displayed in the center of the bandit. RT = Reaction time, ITI: Inter trial interval.

Supplementary Figure 2. Defining directed and random exploration based on the value of the selected bandit (i.e. random exploration equals switching from the best to the worst and directed exploration switching from the best to the second best option) revealed **A**) increased random (t = -2.31, p = 0.019), but not **B**) directed exploration (t = -1.52, p = 0.133) of patients with schizophrenia (SZ) compared to healthy control (HC) participants. * p < 0.05. n.s. = non significant.

Supplementary Figure 3. Centrality analysis shows that high sensitivity C-reactive protein (hsCRP) has the highest strength of all immune-parameters included. For a list of abbreviations see **Table S2**.

Supplementary Figure 4. Bootstrap based significance testing of non-zero estimated edge-weights of the network shown in **Fig. 2B**. Non-significant differences between edge weights are indicated by gray boxes, significant differences by black boxes. Significance is based on $\alpha = 0.05$. The colour of the diagonal boxes (ranging from red to blue) corresponds to the weights of the edges, with red indicating negative and blue positive weights. For a list of abbreviations see **Supplementary Table 2**.

Supplementary Figure 5. Bootstrap based significance testing of node strength for the nodes of the network shown in **Fig. 2B**. Non-significant differences between strength of

two nodes are indicated by gray boxes, significant differences by black boxes. Node strength of each node is presented by the number in the white boxes. For a list of abbreviations see **Supplementary Table 2**.

Supplementary Figure 6. The average correlation between bootstrap centrality measures of the network estimated with all cases and networks in which some cases were dropped. For a list of abbreviations see **Supplementary Table 2**.

Supplementary Figure 7. Bootstrapped 95% confidence intervals for estimated edge weights of the network shown in Fig. 2B. For a list of abbreviations see Supplementary Table 2.


Supplementary Table 1. Exploitation and random exploration correlate with the Positive and Negative Syndrome Scale (PANSS) disorganized factor but not with PANSS negative, positive or depressive factor or cognitive score. There are no associations between task parameters and chlorpromazine equivalents.


Supplementary Table 2. Abbreviations of immune parameters.


Supplementary Table 3. Group differences of measured peripheral immune parameters. Units: hsCRP: mg/l; immune parameters: normalized protein expression (NPX). For a list of abbreviations see **Supplementary Table 2**. Statistics: ¹Student's t-test. ²Mann-Whitney U test.

Supplementary Table 4. Significant correlation between random exploration with high sensitivity C-reactive protein (hsCRP), but not with TRAIL or CCL20.


Supplementary Figures Supplementary Figure 1









5






7

Supplementary Figure 6





٠

Bootstrap mean • Sample

Supplementary Tables

Correlations between task-parameters and psychopathology, composite cognitive score and chlorpromazine equivalents in patients with SZ

Supplementary	PANSS	PANSS	PANSS	PANSS	Composite	Chlorpro-
Table 1	negative	positive	disorganized	depressive	cognitive	mazine
	factor	factor	factor	factor	score	equivalents
Total Points	r(s) = -0.07,	r(s) = -0.09,	r(s) = -0.30,	r(s) = 0.23,	r(s) = 0.07,	r(s) = -0.21,
earned	<i>p</i> = 0.678	<i>p</i> = 0.582	<i>p</i> = 0.055	<i>p</i> = 0.141	<i>p</i> = 0.654	<i>p</i> = 0.172
Exploitation	r(s) = -0.09,	r(s) = 0.15,	r(s) = -0.36,	r(s) = 0.105,	r(s) = 0.16,	r(s) = -0.22,
	<i>p</i> = 0.558	<i>p</i> = 0.328	<i>p</i> = 0.018	<i>p</i> = 0.501	<i>p</i> = 0.303	<i>p</i> = 0.159
Random	r(s) = 0.14,	r(s) = -0.17,	r(s) = 0.31,	r(s) = -0.07,	r(s) = -0.18,	r(s) = 0.23,
exploration	<i>p</i> = 0.375	<i>p</i> = 0.291	<i>p</i> = 0.045	<i>p</i> = 0.644	<i>p</i> = 0.454	<i>p</i> = 0.132
Directed	r(s) = -0.01,	r(s) = -0.28,	r(s) = 0.27,	r(s) = -0.15,	r(s) = 0.01,	r(s) = 0.15,
exploration	<i>p</i> = 0.967	<i>p</i> = 0.074	<i>p</i> = 0.078	<i>p</i> = 0.337	<i>p</i> = 0.935	<i>p</i> = 0.338

Supplementary Table 2			
Abbreviation	Legend		
ADA	Adenosine Deaminase		
AXIN1	Axin-1		
Beta-NGF	Beta-nerve growth factor		
CASP-8	Caspase-8		
CCL	C-C motif chemokine		
CD	Cluster of differentiation		
CDCP1	CUB domain-containing protein 1		
hsCRP	High sensitive C-reactive protein		
CSF-1	Colony-stimulating factor 1		
CST5	Cystatin-D		
CXCL	C-X-C motif chemokine		
DNER	Delta and notch-like epidermal growth factor-related receptor		
EN-RAGE	Protein S100-A12		
Flt3L	Fms-related tyrosine kinase 3 ligand		
FGF	Fibroblast growth factor		
GDNF	Glial cell line-derived neurotrophic factor		
HGF	Hepatocyte growth factor		
IL	Interleukin		
IL-R	Interleukin receptor		
LAPTGF	Latency-associated peptide transforming growth factor beta-1		
Lif-R	Leukemia inhibitory factor receptor		
MMP	Matrix metalloproteinase		
NT-3	Neurotrophin-3		
OPG	Osteoprotegerin		
OSM	Oncostatin-M		
PD-L1	Programmed cell death 1 ligand 1		
SCF	Stem cell factor		
SLAMF1	Signaling lymphocytic activation molecule family member 1		
SIRT2	SIR2-like protein 2		
ST1A1	Sulfotransferase 1A1		
STAMPB	STAM-binding protein		
TGF	Transforming growth factor		
TNFB	Tumor necrosis factor beta		
TNFRSF9	Tumor necrosis factor receptor superfamily member 9		
TNFSF14	Tumor necrosis factor ligand superfamily member 14		
TRANCE	Tumor necrosis factor-related activation-induced cytokine		
TWEAK	Tumor necrosis factor (ligand) superfamily, member 12		
TRAIL	Tumor necrosis factor related apoptosis-inducing ligand		
uPA	Urokinase-type plasminogen activator		
VEGFA	Vascular endothelial growth factor		

List of abbreviations of inflammatory parameters

Supplementary Table 3	HC (n = 19)	SZ (n = 45)	Test statistics	
			(t ¹ /U ²)	p
ADA	3.96 (0.61)	3.75 (0.62)	U = 272.5	p = 0.157
AXIN1	5.13 (2.07)	5.09 (1.40)	U = 348.0	p = 0.880
Beta-NGF	1.54 (0.24)	1.44 (0.17)	t = 1.899	p = 0.063
CASP-8	1.95 (1.26)	1.55 (0.87)	U = 324.5	<i>p</i> = 0.586
CCL2	9.54 (0.37)	9.78 (0.43)	t = -2.046	p = 0.045
CCL3	4.20 (0.50)	4.35 (0.56)	U = 288.0	p = 0.248
CCL4	6.12 (0.48)	6.18 (0.65)	t = -0.317	p = 0.753
CCL7	0.82 (0.37)	1.15 (0.53)	t = -2.234	p = 0.030
CCL8	7.89 (0.59)	7.62 (0.74)	U = 265.5	p = 0.126
CCL11	7.16 (0.38)	7.52 (0.48)	t = -2.741	p = 0.008
CCL13	3.49 (0.74)	3.40 (0.76)	U = 327.0	p = 0.616
CCL19	8.63 (1.09)	8.58 (0.62)	U = 334.5	p = 0.706
CCL20	4.55 (0.57	5.55 (1.26)	U = 158.5	p < 0.001
CCL23	9.63 (0.39)	9.49 (0.48)	t = 1.085	p = 0.282
CCL25	5.74 (0.65)	5.96 (0.55)	t = -1.320	p = 0.192
CCL28	1.10 (0.43)	0.89 (0.47)	U = 183.5	p = 0.003
CD5	4.77 (0.27)	4.75 (0.42)	U = 326.0	p = 0.604
CD6	4.45 (0.45)	4.19 (0.50)	t = 1.837	p = 0.071
CD40	10.14 (0.68)	9.91 (0.62)	U = 281.5	p = 0.206
CD244	6.06 (0.63)	5.84 (0.56)	U = 271.0	p = 0.150
CDCP1	2.21 (0.51)	2.45 (0.53)	U = 259.5	p = 0.103
hsCRP	0.89 (0.63)	2.18 (1.80)	U = 243.5	<i>p</i> = 0.007
CSF-1	7.78 (0.25)	7.76 (0.23)	t = 0.232	p = 0.818
CST5	5.82 (0.49)	5.70 (0.57)	U = 297.5	p = 0.319
CXCL1	8.77 (1.02)	8.59 (0.92)	t = 0.648	p = 0.520
CXCL5	11.28 (1.47)	10.96 (1.16)	U = 335.0	p = 0.320 p = 0.713
CXCL6	8.19 (1.27)	7.85 (1.06)	U = 309.5	p = 0.427
CXCL9	6.82 (1.05)	6.63 (0.54)	U = 350.0	p = 0.427 p = 0.907
CXCL10	7.75 (1.04)	7.42 (0.75)	U = 287.5	p = 0.307 p = 0.245
CXCL11	7.85 (1.03)	7.23 (1.15)	U = 223.0	<i>p</i> = 0.245
CX3CL1	4.92 (0.35)	4.81 (0.35)	t = 1.078	p = 0.020 p = 0.286
DNER	7.94 (0.24)	7.99 (0.29)	t = -0.532	p = 0.280 p = 0.597
EN-RAGE	1.64 (0.87)	1.76 (0.75)	U = 325.5	p = 0.598
Flt3L	8.48 (0.52)	8.54 (0.54)	t = -0.405	p = 0.598 p = 0.687
FGF-5			t = -0.405 t = 1.225	p = 0.087 p = 0.226
FGF-19	1.00 (0.20) 7.95 (0.93)	0.93 (0.20) 7.67 (0.83)	t = 1.225 t = 1.133	p = 0.220 p = 0.262
FGF-19	4.56 (1.35)	5.34 (1.20)	t = -2.186	p = 0.202 p = 0.033
FGF-23	1.85 (0.51)	· · · ·	U = 279.5	p = 0.035 p = 0.195
GDNF	1.38 (0.41)	1.95 (0.36)	U = 303.5	p = 0.195 p = 0.371
HGF		7.82 (0.36)		1
IL-6	7.70 (0.34)	3.01 (0.91)	t = -1.203	<i>p</i> = 0.234 <i>p</i> = 0.025
IL-0 IL-7	2.47 (0.51)	. ,	t = -2.308	p = 0.025 p = 0.299
IL-8	3.91 (0.93)	3.62 (0.87)	U = 295.0	
	5.18 (0.56)	5.27 (0.57)	t = -0.596	p = 0.554
IL-10	2.73 (1.28)	2.67 (0.52)	U = 281.5	p = 0.206
IL-10RA	1.44 (0.98)	1.36 (1.29)	U = 285.0	p = 0.228
IL-10RB	6.38 (0.25)	6.43 (0.26)	t = -0.673	p = 0.504
IL-12B	4.10 (0.66)	4.00 (0.78)	t = 0.448	p = 0.656
IL-15RA	0.11 (0.18)	0.11 (0.20)	U = 350.0	p = 0.907
IL-17C	1.38 (0.42)	1.61 (0.56)	t = -1.547	p = 0.127
IL-18	7.49 (0.47)	7.54 (0.47)	t = -0.369	p = 0.713
IL-18R1	6.66 (0.46)	6.71 (0.33)	t = -0.465	p = 0.643
K4E-BP1 LAPTGF	8.69 (1.50)	8.55 (1.08) 7.23 (0.60)	t = 0.409 U = 250.0	p = 0.684
	7.57 (0.72)	· · · /		p = 0.073
Lif-R	2.30 (0.25)	2.29 (0.23)	U = 347.5	p = 0.874
MMP-1	11.98 (1.46)	11.68 (1.17)	t = 0.823	p = 0.414
MMP-10	5.34 (0.46)	5.46 (0.68)	U = 344.0	p = 0.828
NT-3	1.82 (0.34)	1.81 (0.39)	U = 331.0	p = 0.663
OPG	10.31 (0.38)	10.15 (0.29)	t = 1.743	<i>p</i> = 0.087
OSM	2.31 (0.70)	2.47 (0.98)	t = -0.576	p = 0.567
PD-L1	3.58 (0.36)	3.52 (0.34)	t = 0.576	<i>p</i> = 0.567
SCF	9.65 (0.39)	9.40 (0.42)	t = 2.125	<i>p</i> = 0.038
SLAMF1	1.27 (0.46)	1.15 (0.37)	t = 1.067	<i>p</i> = 0.291

SIRT2	4.37 (2.11)	4.11 (1.47)	U = 352.0	<i>p</i> = 0.933
ST1A1	2.96 (1.35)	2.68 (1.00)	U = 316.0	<i>p</i> = 0.493
STAMPB	5.59 (1.80)	5.35 (1.25)	U = 352.0	<i>p</i> = 0.933
TGF-alpha	2.34 (0.25)	2.38 (0.26)	t = -0.458	<i>p</i> = 0.649
TNF-beta	3.57 (0.31)	3.58 (0.45)	t = -0.091	<i>p</i> = 0.928
TNFRSF9	5.72 (0.40)	5.87 (0.40)	t = -1.282	<i>p</i> = 0.205
TNFSF14	4.53 (0.91)	4.43 (0.70)	U = 349.0	<i>p</i> = 0.893
TRAIL	7.94 (0.44)	8.31 (0.24)	t = -4.164	p < 0.001
TRANCE	4.06 (0.74)	4.47 (0.67)	t = -2.087	p = 0.041
TWEAK	9.33 (0.42)	9.20 (0.43)	t = 1.076	<i>p</i> = 0.286
uPA	10.24 (0.24)	10.29 (0.30)	t = -0.548	<i>p</i> = 0.586
VEGFA	9.31 (0.44)	9.33 (0.50)	U = 335.0	<i>p</i> = 0.719

Supplementary	Total points earned	Continuously best (N)	Shifts to less informative	Shifts to more informative
Table 4	(Reward)	(Exploitation)	option (N) (Random	option (N) (Directed
			Exploration)	Exploration)
hsCRP	r(s) = -0.19, <i>p</i> = 0.225	r(s) = -0.27, <i>p</i> = 0.081	r(s) = 0.40, <i>p</i> = 0.008	r(s) = 0.17, <i>p</i> = 0.284
TRAIL	r(p) = -0.11, <i>p</i> = 0.517	r(p) = -0.12, <i>p</i> = 0.445	r(s) = 0.19, <i>p</i> = 0.248	r(s) = 0.16, p = 0.326
CCL20	r(s) = -0.21, <i>p</i> = 0.196	r(s) = 0.06, <i>p</i> = 0.737	r(s) = 0.10, <i>p</i> = 0.557	r(s) = 0.13, p = 0.414

Correlations between hsCRP, TRAIL and CCL20 with bandit task parameters in patients with SZ